INO — Inovio Pharmaceuticals, Inc.
INO dilution and offerings
- Dilution risk: Critical
- Active shelf: S-3 (Jul 2026)
- Float: 81.0M shares
Dilution filings
$0.6024-21.95%
Last close: · regular session
After-hours $2.06 +241.97% ·
Last 60 sessions
Dilution risk: critical; active shelf registration (S-3, Jul 2026). Float: 81.0M shares. Latest SEC filing: 8-K on Oct 6, 2026. INO closed at $0.6024 (-21.95%) on Oct 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for INO in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 112
- Website: https://www.inovio.com
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Latest SEC filings for INO
Latest INO news
- Inovio Pharmaceuticals (INO) Soars 280% After FDA Approves Vocer
- INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) Read article
- Why is Inovio Pharmaceuticals stock surging today?
- Inovio surges 280% following FDA approval of Voceryq for rare disease (INO:NASDAQ)
- Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
- When the Price of (INO.UN) Talks, People Listen (INO.UN:CA)
- Inovio Pharmaceuticals stock faces FDA decision for INO-3107
- Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.